Work 365 Sync for Self-Service and Provisioning Automation

Work 365 Sync for Self-Service and Provisioning Automation

Work 365 Sync solves significant provisioning and customer self-service challenges faced by Microsoft Partners

PR Newswire

RESTON, Va., Aug. 16, 2019 /PRNewswire/ — IOTAP, a Microsoft Gold Partner, announced the release of its Work 365 Sync application at this year’s Microsoft Inspire Conference in Las Vegas. Work 365 Sync solves a critical service automation challenge by enabling self-service for their end-customers and provisioning automation for Partners in the CSP Program. Work 365 Sync is a light weight easy to setup solution for partners to bring all the Partner Center and provisioning data right into Dynamics 365.

Work 365 Sync is part of the Work 365 application suite, which solves common pain points such as Microsoft license management, subscription management and billing automation.Work 365 Sync is built on Dynamics 365 and provides integration for Direct and Indirect partners further extending the applications partners are already using. Partners start a trial and can use Sync to quickly provision subscriptions, track azure usage, manage the cloud relationship and enable self-service.

“Work 365 Sync helps Partners that are not looking for billing or invoice automation to still scale their cloud services business, for a fixed annual investment,” said Ismail Nalwala, CEO of IOTAP. “As Dynamics 365 users and Microsoft Partners ourselves, we know how important self-service, provisioning and customer data is to us and our users.”

To learn more about the latest version of Work 365 as well as Work 365 Sync, visit


Press release distributed by PRLog


Cision View original content:


Oncopeptides Announces Acceptance of Data for Presentation at International Myeloma Workshop, September 12-15

Oncopeptides Announces Acceptance of Data for Presentation at International Myeloma Workshop, September 12-15

PR Newswire

STOCKHOLM, Aug. 16, 2019 /PRNewswire/ — Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today the acceptance of an oral late breaking presentation providing updated melflufen data from the Phase 2 pivotal OP-106 HORIZON study as well as two poster presentations at the 17th International Myeloma Workshop (IMW) meeting (September 12-15, Boston, Massachusetts, USA).

Melflufen is a lipophilic peptide-conjugated alkylator belonging to a novel class of Peptidase Enhanced Cytotoxics (PEnC) and is presently being evaluated in a broad global clinical development program.

Comment from CEO Jakob Lindberg
“We are looking forward to the upcoming IMW meeting.  IMW is an important myeloma-specific meeting held every two years.  Professor Paul G. Richardson will be presenting data from the phase 2 HORIZON study at the oral late breaking session on melflufen’s activity in patients with relapsed-refractory multiple myeloma (RRMM) and extra medullary disease (EMD).  At the European Hematology Association (EHA) in June, interim data were presented suggesting that melflufen may be the first drug to exhibit meaningful activity in this difficult to treat EMD patient population. To our knowledge, HORIZON represents the largest clinical trial cohort of EMD patients to date and there is a clear unmet medical need in this rapidly growing patient population” said Jakob Lindberg, CEO Oncopeptides. “Melflufen, in combination with dexamethasone, demonstrates encouraging activity in advanced RRMM patients with EMD. Response rates appear higher than observed in prior studies and this could be linked to melflufen’s unique mechanism of action. These results are encouraging, and we continue to monitor this patient group in ongoing and future clinical trials”. 

Upcoming presentations at IMW
The HORIZON data will be presented as an oral presentation by Professor Paul G. Richardson, in the plenary session “Late Breaking Abstracts” on Sunday, September 15 at 08.30 AM (ET) (14.30 CET) under the title: Activity of Melflufen in RRMM Patients with Extramedullary Disease in the Phase 2 HORIZON Study (OP-106) – Promising Results in a High-Risk Population.

The first poster presentation will be held during Poster Session I, Multiple Myeloma Genomics – Friday, September 13 at 6.30 – 8.00 PM (ET) (Saturaday, September 14 at 00.30 – 02.00 CET) under the title: Aminopeptidase gene expression in myeloma.

The second poster presentation will be held during Poster Session II, Treatment of Previously Treated Myeloma – Saturday, September 14 at 12.30 – 2.00 PM (ET) (18.30 – 20.00 CET) under the title: Quality of life treatment for relapsed/refractory multiple myeloma, a systematic review.

Paul G. Richardson, MD, is Professor of Medicine at Harvard Medical School and Clinical Program Leader, Director of Clinical Research at the Jerome Lipper Multiple Myeloma Center Dana-Farber Cancer Institute in Boston, Massachusetts, USA.

About the OP-106 HORIZON study
Patient recruitment in the pivotal HORIZON study is ongoing. The goal is to include 150 patients in the study with the last patient included during Q3 2019. The patients in the study are refractory to pomalidomide and/or daratumumab after failing on immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). Interim data were presented at the EHA meeting in June based on a data cut-off dated May 6th 2019 with 121 patients treated, out of which 108 patients had recivied two or more cycles of treatment.

Oncopeptides has initiated preparations for submitting a New Drug Application (NDA) for accelerated approval of melflufen in the US based on the available HORIZON data. The detailed plan for the filing process is still under development, but Oncopeptides currently targets to submit the application to FDA during the first quarter of 2020. This could then lead to the first melflufen market approval in the US in 2020.

More information can be found at:

About Melflufen
Melflufen is a lipophilic peptide-conjugated alkylator that rapidly delivers a highly cytotoxic payload into myeloma cells through peptidase activity. It belongs to the novel class Peptidase Enhanced Cytotoxics (PEnC), which is a family of lipophilic peptides that exhibit increased activity via peptidase cleavage and have the potential to treat many cancers.  Peptidases play a key role in protein homeostasis and feature in cellular processes such as cell-cycle progression and programmed cell death. Melflufen is rapidly taken up by myeloma cells due to its high lipophilicity and immediately cleaved by peptidases to deliver an entrapped hydrophilic alkylator payload. In vitro, melflufen is 50-fold more potent in myeloma cells than the alkylator payload itself due to the peptidase cleavage, and induces irreversible DNA damage and apoptosis. Melflufen displays cytotoxic activity against myeloma cell lines resistant to other treatments, including alkylators, and has also demonstrated inhibition of DNA repair induction and angiogenesis in preclinical studies.

About Oncopeptides 
Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological cancers. The company is focusing on the development of the lead product candidate melflufen, a novel lipophilic peptide conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Cytotoxics (PEnC). Melflufen is in development as a new treatment for the hematological cancer multiple myeloma, including the Phase 2 pivotal trial HORIZON currently underway and a global confirmatory Phase 3 trial (OP-103 OCEAN) continuing enrollment. Oncopeptides’ headquarters is located in Stockholm, Sweden, and the company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.

For further information, please contact:
Jakob Lindberg, CEO of Oncopeptides
Telephone: +46 8 615 20 40

Rein Piir, Head of Investor Relations at Oncopeptides
Cell phone: +46 70 853 72 92

This information was submitted for publication at 22.00 CET September 16, 2019

This information was brought to you by Cision–septem,c2882871

The following files are available for download:

Press release – Acceptance of Data for Presentation at IMW 2019


Cision View original content:

SOURCE Oncopeptides AB

Crystal Group Takes Complexity Out of Data Security with Innovative Military-Grade NAS Capabilities


Crystal Group Takes Complexity Out of Data Security with Innovative Military-Grade NAS Capabilities

Company to showcase turnkey advanced, military-grade Network Attached Storage system at DoDIIS Conference

PR Newswire

HIAWATHA, Iowa, Aug. 16, 2019 /PRNewswire/ – Crystal Group, Inc., a leading designer and manufacturer of rugged computer and electronic hardware, announced today the availability of its latest Network Attached Storage (NAS) solution to ensure hardware-level protection of data classified as top secret and below. The versatile and easily-deployable system withstands the dynamic environments of multi-domain battlefields and expands cybersecurity to the tactical edge. The rugged and secure high-performance storage system will debut at DoDIIS in Crystal Group’s booth #749.

Crystal Group Logo, Hiawatha, IA

This multipurpose storage solution provides FIPS 140-2 certified data encryption with near-zero latency, instant data destruction and integrated key management. Addressing these critical needs along with strict U.S. Department of Defense quality and security requirements with a turnkey, scalable NAS system reinforces Crystal Group’s proven track record for delivering reliable data handling and security at the edge.

“With a secure, rugged NAS solution that dependably operates in all conditions and is optimized to process and store data at near-zero latency, our customers gain a tactical advantage and confidence that mission-critical data is protected,” said Jim Shaw, executive vice president of Engineering at Crystal Group.

Meeting MIL-SPEC environmental performance and NIST compliance, this system is ideal for a myriad of defense applications in any domain. The low SWaP solution is comprised of the Crystal Group’s FORCE™ rugged storage server, RCS7450 network switch, small form factor rugged embedded computer and 19″ rugged display integrated in a rugged transit case for mobile and tactical environments.  

Key features include:

  • CSfC elements with IPsec and AES256 encryption
  • FIPS 140-2 certified data encryption and key management
  • Near-zero latency and end-to-end encryption capabilities, providing secure, real-time data processing critical to threat response
  • Chassis intrusion detection with options for instant data destruction and key recovery
  • Tamper evident security coatings
  • Data-in-transit and data-at-rest protection with network access control and support for multi-tenant networks

Crystal Group FORCETM rugged servers are designed for tactical military deployments in volatile environments. This high-reliability system includes Intel® Xeon® Cascade Lake scalable processors and can be configured with up to 12 different modules that offer high-speed communication, expanded storage capacity, audio and enhanced security to meet your specific operating needs.

The Crystal Group RCS7450 switch supports up to 48 copper or fiber ports, uses open standard protocols and offers advanced stacking capabilities. The system can be configured with an IPsec module to enable end-to-end encryption tunnels from the edge to the core.

Crystal Group will be showcasing it’s latest NAS solution on August 18-21, 2019 at the Department of Defense Intelligence Information System (DoDIIS) Worldwide Conference in Tampa, FL in booth #749.

Click here to learn more.

About Crystal Group, Inc.

Crystal Group, Inc., a technology leader in rugged computer hardware, specializes in the design and manufacture of custom and commercial rugged servers, embedded computing, networking devices, displays, power supplies and data storage for high reliability in harsh environments. An employee-owned small business founded in 1987, Crystal Group provides the defense, government and industrial markets with in-house customization, engineering, integration, configuration management, product lifecycle planning, warranty and support services.

Crystal Group products meet or exceed IEEE, IEC and military standards, including MIL-STD-810, 167-1, 461 and MIL-S-901, are backed by an industry-leading, 5-plus-year warranty with in-house support and are manufactured in the company’s Hiawatha, Iowa, USA, facility certified to AS9100D quality management standards.

© 2019 Crystal Group, Inc. All rights reserved. All marks are property of their respective owners. Design and specifications are subject to change.

Cision View original content to download multimedia:

SOURCE Crystal Group, Inc.